J&J Boosts Orphan Drug Portfolio with US$30 B Takeover of Actelion’s Marketed and Late-Stage Assets
By Jasmine Kalsi, Vipul Sikka & Heather Cartwright
Pharma Deals Review: Vol 2017 Issue 2 (Table of Contents)
Published: 15 Feb-2017
DOI: 10.3833/pdr.v2017.i2.2225 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In its largest pharmaceutical deal to date, Johnson & Johnson (J&J) will acquire the marketed and late-stage product portfolios of the Swiss biotech Actelion for approximately US$30 B in cash...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS